{"id":"imatinib-mesylate-and-nilotinib","safety":{"commonSideEffects":[{"rate":"50–70%","effect":"Nausea"},{"rate":"20–40%","effect":"Vomiting"},{"rate":"30–50%","effect":"Diarrhea"},{"rate":"20–40%","effect":"Muscle cramps"},{"rate":"10–30%","effect":"Rash"},{"rate":"5–20%","effect":"Edema"},{"rate":"10–30%","effect":"Elevated liver enzymes"},{"rate":"10–40%","effect":"Myelosuppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs inhibit the BCR-ABL fusion protein tyrosine kinase, which drives chronic myeloid leukemia (CML) pathogenesis. Imatinib was the first-generation inhibitor, while nilotinib is a second-generation inhibitor with improved potency and selectivity. The combination or sequential use may be evaluated in Phase 3 trials to overcome resistance or improve efficacy in CML patients.","oneSentence":"Imatinib and nilotinib are tyrosine kinase inhibitors that block BCR-ABL and other oncogenic kinases to suppress abnormal cell proliferation in chronic myeloid leukemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:38.109Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML), chronic phase"},{"name":"CML with BCR-ABL mutations or imatinib resistance"}]},"trialDetails":[{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT04971226","phase":"PHASE3","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","enrollment":406},{"nctId":"NCT04877522","phase":"PHASE4","title":"Asciminib Roll-over Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-30","conditions":"Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive","enrollment":347},{"nctId":"NCT03516279","phase":"PHASE2","title":"Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-06-26","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease","enrollment":40},{"nctId":"NCT07413263","phase":"","title":"Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-01","conditions":"Chronic Myeloid Leukemia","enrollment":75},{"nctId":"NCT03610971","phase":"PHASE2","title":"Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-19","conditions":"Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase","enrollment":24},{"nctId":"NCT02891395","phase":"PHASE2","title":"Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2012-12-24","conditions":"Graft Versus Host Disease","enrollment":65},{"nctId":"NCT04626024","phase":"PHASE2","title":"Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2020-12-22","conditions":"Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission","enrollment":100},{"nctId":"NCT03654768","phase":"PHASE2","title":"Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-10-24","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":81},{"nctId":"NCT03578367","phase":"PHASE2","title":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-22","conditions":"CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic","enrollment":104},{"nctId":"NCT07188428","phase":"","title":"Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-27","conditions":"Leukemia, Chronic Myeloid","enrollment":2298},{"nctId":"NCT07151820","phase":"","title":"A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Leukemia, Chronic Myeloid","enrollment":2546},{"nctId":"NCT01698905","phase":"PHASE2","title":"Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-20","conditions":"Chronic Myeloid Leukemia","enrollment":163},{"nctId":"NCT07091019","phase":"","title":"A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-15","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":1000},{"nctId":"NCT01860456","phase":"","title":"TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2013-05","conditions":"Chronic Myeloid Leukemia","enrollment":412},{"nctId":"NCT01751425","phase":"PHASE1","title":"Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-07-24","conditions":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease","enrollment":8},{"nctId":"NCT01804985","phase":"PHASE2","title":"De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2013-12","conditions":"Chronic Myeloid Leukaemia","enrollment":174},{"nctId":"NCT03906292","phase":"PHASE2","title":"Frontline Asciminib Combination in Chronic Phase CML","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Jena","startDate":"2019-08-19","conditions":"Chronic Myeloid Leukemia","enrollment":125},{"nctId":"NCT04126681","phase":"PHASE2","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-10-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":144},{"nctId":"NCT05682924","phase":"","title":"Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib","status":"RECRUITING","sponsor":"Samara State Medical University","startDate":"2022-10-01","conditions":"Chronic Myeloid Leukaemia","enrollment":105},{"nctId":"NCT04147533","phase":"PHASE2","title":"Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masaryk University","startDate":"2020-06-16","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug","enrollment":150},{"nctId":"NCT06692803","phase":"","title":"Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-23","conditions":"Chronic Myeloid Leukemia","enrollment":2043},{"nctId":"NCT02326311","phase":"PHASE3","title":"Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2015-06-10","conditions":"Leukemia, Chronic Myeloid","enrollment":229},{"nctId":"NCT02001818","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia","status":"COMPLETED","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2014-04-11","conditions":"Chronic Myeloid Leukaemia","enrollment":60},{"nctId":"NCT02081378","phase":"PHASE1","title":"A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04-24","conditions":"Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","enrollment":326},{"nctId":"NCT05286528","phase":"","title":"Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-11-18","conditions":"Chronic Myeloid Leukaemia","enrollment":1484},{"nctId":"NCT04681820","phase":"","title":"Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2020-11-01","conditions":"CML-CP; Mutation;Suboptimal Response or Failure in TKI","enrollment":200},{"nctId":"NCT04518644","phase":"","title":"Nilotinib, for Patients With CML-CP or CML-AP","status":"NO_LONGER_AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Chronic Myelogenous Leukemia (CML)","enrollment":""},{"nctId":"NCT02269267","phase":"PHASE2","title":"The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2014-12-18","conditions":"Leukemia, Myeloid, Chronic","enrollment":173},{"nctId":"NCT05743465","phase":"","title":"A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-10-06","conditions":"Leukemia","enrollment":1769},{"nctId":"NCT00573378","phase":"PHASE2","title":"Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-09","conditions":"Chronic Myeloid Leukemia","enrollment":12},{"nctId":"NCT03885830","phase":"","title":"Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-06-20","conditions":"CML, Chronic Phase, CML (Chronic Myelogenous Leukemia, CML - Philadelphia Chromosome","enrollment":45},{"nctId":"NCT03045120","phase":"","title":"Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-07-19","conditions":"Chronic Phase Chronic Myeloid Leukemia","enrollment":118},{"nctId":"NCT01370980","phase":"","title":"Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment","status":"COMPLETED","sponsor":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","startDate":"2010-07","conditions":"Cancer","enrollment":43},{"nctId":"NCT05619978","phase":"","title":"French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-03","conditions":"Chronic Myeloid Leukemia","enrollment":200},{"nctId":"NCT01475110","phase":"","title":"Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2012-09-13","conditions":"Chronic Myeloid Leukaemia","enrollment":19},{"nctId":"NCT01025505","phase":"PHASE2","title":"Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2012-06","conditions":"Treatment, Stem Cell Transplantation","enrollment":40},{"nctId":"NCT04006847","phase":"PHASE1, PHASE2","title":"Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-09-14","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":1},{"nctId":"NCT01244750","phase":"","title":"Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12-02","conditions":"Chronic Myeloid Leukemia","enrollment":1494},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT04326933","phase":"","title":"Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-01-01","conditions":"Patients Diagnosed as Chronic Meyloid Leukemia","enrollment":40},{"nctId":"NCT00769327","phase":"PHASE2","title":"Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2009-02-09","conditions":"Leukemia","enrollment":129},{"nctId":"NCT02627677","phase":"PHASE3","title":"A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"Ariad Pharmaceuticals","startDate":"2015-12-31","conditions":"Chronic Phase Chronic Myeloid Leukemia","enrollment":44},{"nctId":"NCT00644878","phase":"PHASE2","title":"Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":18},{"nctId":"NCT00980018","phase":"PHASE4","title":"An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Chronic Myelogenous Leukemia","enrollment":52},{"nctId":"NCT00109707","phase":"PHASE1, PHASE2","title":"A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-04","conditions":"Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome","enrollment":507},{"nctId":"NCT01844765","phase":"PHASE2","title":"Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08-20","conditions":"Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia","enrollment":59},{"nctId":"NCT01077544","phase":"PHASE1","title":"A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04-14","conditions":"Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":15},{"nctId":"NCT00471497","phase":"PHASE3","title":"A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07-31","conditions":"Myelogenous Leukemia, Chronic","enrollment":846},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT04578847","phase":"PHASE2","title":"A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)","status":"UNKNOWN","sponsor":"National Research Center for Hematology, Russia","startDate":"2020-01-15","conditions":"Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia","enrollment":100},{"nctId":"NCT03880617","phase":"","title":"Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-03-25","conditions":"CML, GIST","enrollment":297},{"nctId":"NCT01744665","phase":"PHASE2","title":"A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08-12","conditions":"CML","enrollment":59},{"nctId":"NCT00036738","phase":"PHASE2","title":"Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2001-07-13","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blastic Phase","enrollment":28},{"nctId":"NCT00976612","phase":"","title":"Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-01","conditions":"Gastrointestinal Stromal Tumors","enrollment":17},{"nctId":"NCT02174445","phase":"PHASE3","title":"An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years","status":"TERMINATED","sponsor":"Prof. Dr. Nikolas von Bubnoff","startDate":"2014-03","conditions":"Chronic Myeloid Leukemia","enrollment":14},{"nctId":"NCT02611492","phase":"PHASE3","title":"A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04","conditions":"Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia","enrollment":265},{"nctId":"NCT03907670","phase":"","title":"Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-10-01","conditions":"Chronic Phase Chronic Myelogenous Leukemia","enrollment":45},{"nctId":"NCT02272777","phase":"PHASE3","title":"A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-07-17","conditions":"Leukemia","enrollment":225},{"nctId":"NCT02421926","phase":"","title":"Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)","status":"WITHDRAWN","sponsor":"Asan Medical Center","startDate":"2014-10","conditions":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","enrollment":""},{"nctId":"NCT02142036","phase":"PHASE2","title":"N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2014-05","conditions":"Metastatic Cancer","enrollment":50},{"nctId":"NCT01397734","phase":"PHASE1","title":"Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2011-09","conditions":"Chronic Myelogenous Leukemia","enrollment":7},{"nctId":"NCT01602952","phase":"PHASE1, PHASE2","title":"Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2008-07","conditions":"Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive","enrollment":85},{"nctId":"NCT01883219","phase":"PHASE2","title":"TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-06","conditions":"Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation, Minimal Residual Disease","enrollment":80},{"nctId":"NCT03331211","phase":"","title":"Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-11-01","conditions":"Leukemia, Lymphoblastic, Acute","enrollment":100},{"nctId":"NCT02108951","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-07-07","conditions":"Philidelphia Positive Chronic Myeloid Leukaemia","enrollment":20},{"nctId":"NCT00702403","phase":"PHASE1, PHASE2","title":"Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-08-14","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Blastic Phase Chronic Myelogenous Leukemia","enrollment":40},{"nctId":"NCT03214718","phase":"NA","title":"Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-08-05","conditions":"Chronic Myeloid Leukemia Patients","enrollment":50},{"nctId":"NCT03205267","phase":"PHASE2","title":"Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients","status":"UNKNOWN","sponsor":"University of Bonn","startDate":"2016-03","conditions":"Chronic Myelogenous Leukaemia","enrollment":127},{"nctId":"NCT00633295","phase":"PHASE2","title":"Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06","conditions":"Gastrointestinal Stromal Tumors (GIST)","enrollment":9},{"nctId":"NCT01098500","phase":"","title":"Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Cancer","enrollment":3800},{"nctId":"NCT02086487","phase":"PHASE4","title":"Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy","status":"TERMINATED","sponsor":"King Abdullah International Medical Research Center","startDate":"2013-03","conditions":"Myeloid Leukemia, Chronic","enrollment":98},{"nctId":"NCT00264160","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Leukemia, Myeloid, Chronic","enrollment":36},{"nctId":"NCT00718562","phase":"PHASE2","title":"Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-09","conditions":"Gastrointestinal Stromal Tumors","enrollment":35},{"nctId":"NCT01289028","phase":"PHASE3","title":"Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-11","conditions":"Gastrointestinal Stromal Tumors","enrollment":125},{"nctId":"NCT01073436","phase":"","title":"Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-05","conditions":"Chronic Myeloid Leukemia","enrollment":7},{"nctId":"NCT00760877","phase":"PHASE3","title":"Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06","conditions":"CHRONIC MYELOGENOUS LEUKEMIA","enrollment":207},{"nctId":"NCT01188278","phase":"","title":"Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-07","conditions":"Leukemia, Myeloid, Chronic-Phase (CML-CP)","enrollment":173},{"nctId":"NCT00785785","phase":"PHASE3","title":"A Study of Nilotinib Versus Imatinib in GIST Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Gastrointestinal Stromal Tumor (GIST)","enrollment":644},{"nctId":"NCT01275196","phase":"PHASE3","title":"Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04","conditions":"Chronic Myeloid Leukemia","enrollment":267},{"nctId":"NCT01254188","phase":"PHASE3","title":"Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04","conditions":"Chronic Myeloid Leukemia","enrollment":421},{"nctId":"NCT00802841","phase":"PHASE3","title":"Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-05","conditions":"Chronic Myelogenous Leukemia","enrollment":191},{"nctId":"NCT01289054","phase":"","title":"A Global Imatinib and Nilotinib Pregnancy Exposure Registry","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"All Indications for Glivec/Gleevec and Tasigna","enrollment":4},{"nctId":"NCT00751036","phase":"PHASE3","title":"Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":94},{"nctId":"NCT01819389","phase":"PHASE3","title":"Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2012-10","conditions":"Leukemia, Myeloid, Chronic, BCR-ABL Positive","enrollment":10},{"nctId":"NCT00441155","phase":"PHASE1","title":"Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Gastrointestinal Stromal Tumors","enrollment":14},{"nctId":"NCT00782834","phase":"PHASE2","title":"Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2008-07","conditions":"Gastrointestinal Stromal Tumors","enrollment":13},{"nctId":"NCT01549548","phase":"","title":"Compassionate Use Ponatinib","status":"NO_LONGER_AVAILABLE","sponsor":"OHSU Knight Cancer Institute","startDate":"","conditions":"Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia","enrollment":""},{"nctId":"NCT00688766","phase":"PHASE3","title":"Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib","status":"TERMINATED","sponsor":"Infinity Pharmaceuticals, Inc.","startDate":"2008-08","conditions":"Gastrointestinal Stromal Tumors","enrollment":47},{"nctId":"NCT00471328","phase":"PHASE3","title":"Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-03","conditions":"Gastrointestinal Stromal Tumors","enrollment":248}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":995,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gleevec","Tasigna"],"phase":"phase_3","status":"active","brandName":"Imatinib Mesylate and Nilotinib","genericName":"Imatinib Mesylate and Nilotinib","companyName":"University Hospital, Lille","companyId":"university-hospital-lille","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imatinib and nilotinib are tyrosine kinase inhibitors that block BCR-ABL and other oncogenic kinases to suppress abnormal cell proliferation in chronic myeloid leukemia. Used for Chronic myeloid leukemia (CML), chronic phase, CML with BCR-ABL mutations or imatinib resistance.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}